Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2023-06-28 Regulatory Filings
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) disclosing a strategic investment by ZIM Laboratories Limited in Australia and the MENA region. It is labeled as a "Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Press Release." The content is an announcement of a business development (strategic investments and partnerships) rather than a financial report or detailed financial data. The document length is 3581 characters, which is relatively short and consistent with a regulatory announcement or press release. There is no financial statement, earnings data, or detailed management discussion. The document is not an annual or interim report, audit report, or earnings release. It is a regulatory announcement informing the market about a material event (strategic investment). Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-06-28 English
Acquisition
M&A Activity Classification · 95% confidence The document is a disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to announcements about significant events or corporate actions. The content details the Board of Directors' approval of an investment in an Australian company and the incorporation of a subsidiary in UAE. It includes annexures with specifics about the acquisitions, such as investment amounts, shareholding percentages, and business objectives. There are no financial statements or detailed financial performance data presented. The document is an announcement of corporate actions related to acquisitions and subsidiary incorporation, fitting the category of M&A Activity (TAR).
2023-06-28 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is an intimation regarding the loss of share certificates and the consequent stop transfer of shares until duplicate certificates are issued. It is addressed to stock exchanges' compliance departments and references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content is about a compliance notification related to share certificate loss and stop transfer, not a financial report, earnings release, or management discussion. It is a regulatory announcement about share transfer status and compliance with listing regulations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) disclosing the schedule of an Investors / Analysts Meet on 27th June 2023. It references compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of material events or information. The document does not contain any financial data, report, or detailed presentation but is an announcement of a scheduled meeting with investors and analysts. It is not a report itself but a regulatory disclosure about an event. Given the nature of the content and the regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-26 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the loss of a share certificate and the consequent stop transfer of shares until a duplicate certificate is issued. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 39(3), which pertains to share certificate loss and transfer restrictions. The content is an official intimation or notification rather than a financial report, audit, or management discussion. It does not contain financial data, earnings, or governance changes but is a regulatory compliance announcement related to share transfer procedures. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated 19.06.2023 from ZIM Laboratories Limited addressed to stock exchanges (BSE and NSE). It discloses the schedule of an Investors/Analysts Meet on 20th June 2023, including the names of participants, venue, and meeting type. The document explicitly states compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of material events or information. There is no financial data, no detailed report, no voting results, no management changes, or other substantive content. The document is essentially an announcement of a scheduled event for investors and analysts. It is short (2193 characters) and serves as a regulatory disclosure notice rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.